Sanjay Popat

Professor of Thoracic Oncology

Institute of Cancer Research

United Kingdom

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Academic Page

Research Interests

Pharmacology

40%

Pharmacotherapy

100%

Cancer Biology

80%

Targeted Therapy

70%

Oncology

70%

Tumor Suppressor

40%

Tyrosine Kinase

30%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles15

Immunotherapy in EGFR-Mutant Non–Small Cell Lung Cancer: End of the Road or the First Chapter?

Article Link

Year:

2024

Familial rare EGFR-mutant lung cancer syndrome: Review of literature and description of R776H family

Article Link

Year:

2024

Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchers

Article Link

Year:

2024

RETaliation—Tackling Rare Resistance Alterations to Osimertinib

Article Link

Year:

2023

A Subset of Non-Small Cell Lung Cancer Patients Treated with Pemetrexed Show 18F-Fluorothymidine “Flare” on Positron Emission Tomography

Article Link

Year:

2023

Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies

Article Link

Year:

2023

Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies

Article Link

Year:

2023

Amivantamab Compared with Real-World Physician’s Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating EGFR Exon 20 Insertion Mutations

Article Link

Year:

2023

Adjuvant immune checkpoint inhibitor therapy for resected non-small-cell lung cancer: dessert, starters, or a sandwich?

Article Link

Year:

2023

Response to letter entitled: Re: ‘Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS exon 19 deletion is not detected by the real-time PCR IdyllaTM EGFR mutation test but is detected by ctDNA NGS and responds to osimertinib'

Article Link

Year:

2022

Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase–positive non–small cell lung cancer using data from ALEX and final results from ALTA-1L

Article Link

Year:

2022

Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer

Article Link

Year:

2022

Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes

Article Link

Year:

2022

Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS exon 19 deletion is not detected by the real-time PCR Idylla™ EGFR mutation test but is detected by ctDNA next generation sequencing and responds to osimertinib

Article Link

Year:

2022

Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)

Article Link

Year:

2022

Collaborators4

Matthew Krebs

Clinical Senior Lecturer

The University of Manchester

UNITED KINGDOM

Pilar Garrido López

Head Medical Oncology Department

HOSPITAL UNIVERSITARIO RAMÓN Y CAJAL

SPAIN

Eric O. Aboagye

Imperial College London

UNITED KINGDOM

Anthonie van der Wekken

University of Groningen

NETHERLANDS

How do I reach out?

Meet Kite AI